US Patent

US7241907 — Acetone solvate of dimethoxy docetaxel and its process of preparation

Composition of Matter · Assigned to Aventis Pharma SA · Expires 2025-12-10 · 0y expired

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the acetone solvate of dimethoxydocetaxel, a specific form of the drug substance, and its process of preparation.

USPTO Abstract

This invention discloses and claims an acetone solvate of dimethoxydocetaxel or 4-acetoxy-2α-benzoyloxy-5β,20-epoxy-1-hydroxy-7β,10β-dimethoxy-9-oxotax-11-en-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate and its preparation by crystallization from an aqueous/acetone solution.

Drugs covered by this patent

Patent Metadata

Patent number
US7241907
Jurisdiction
US
Classification
Composition of Matter
Expires
2025-12-10
Drug substance claim
Yes
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.